Abstract
Objective:
to evaluate how much decreases intraocular pressure (IOP) with TRAVAMED® (travoprost 0,004%) (Germed, Brazil) in patients with primary open angle glaucoma (POAG) and ocular hypertension (OH) and possible side effects.
Methods:
controlled and randomized study, it was evaluated 70 eyes of 38 patients with age of 18 years old or more diagnosed with POAG and OH. All the patients had TRAVAMED® as first drop for treatment used once daily (at night) and 30 days later they had IOP measured by Goldmann tonometry, with the same examiner in the same tonometer at the same times.
Results:
the mean decrease in IOP was 7,46 mmHg after 30 days using the drops. 15.71% (1111 Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111(1):51-5.) of eyes had conjunctival redness, 8.57% (66 Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al.; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-84.) had pain, 8.57% (6) had burning, 2.86% (22 Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703.) had blurring vision and 1.56% (11 Consenso Brasileiro de Glaucoma de Ângulo Aberto. Glaucoma primário de ângulo aberto/Sociedade Brasileira de Glaucoma. São Paulo: PlanMark; 2005.) of the eyes there wasn’t a significant reduction in IOP.
Conclusion:
TRAVAMED® was efficient when evaluating IOP decrease. The most correlated side effects were conjunctival redness (15.71%), pain (8.57%) and burning (8.57%), but studies with longer follow-up are needed.
Keywords:
Glaucoma; Ocular hypertension/drug therapy; Travoprost/adverse effects